Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–E386 (2015).
  Medline CASGoogle Scholar
• 2. Oecd Union E. Health at a Glance: Europe 2018. https://doi.org/10.1787/health_glance_eur-2018-en (2018) (Epub ahead of print).
  Google Scholar
• 3. NIH. SEER Cancer Stat Facts: Prostate Cancer. (2020). https://seer.cancer.gov/statfacts/html/prost.html
  Google Scholar
• 4. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J. Urol. 172(3), 910–914 (2004).
  MedlineGoogle Scholar
• 5. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4), 433–439 (2005).
  Medline CASGoogle Scholar
• 6. Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14(2), 149–158 (2013).
  Medline CASGoogle Scholar
• 7. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737–746 (2015). • Describes the results of the CHAARTED trial concerning docetaxel chemotherapy in metastasized hormone sensitive prostate cancer (mHSPC) patients and helped to establish docetaxel as the first additional treatment option to androgen deprivation therapy (ADT) in high-volume disease.
  Medline CASGoogle Scholar
• 8. Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann. Oncol. 26(8), 1660–1667 (2015).
  Medline CASGoogle Scholar
• 9. Berthold DR, Pond GR, Soban F, De Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26(2), 242–245 (2008).
  Medline CASGoogle Scholar
• 10. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147–1154 (2010).
  MedlineGoogle Scholar
• 11. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369(3), 213–223 (2013).
  Medline CASGoogle Scholar
• 12. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
  Medline CASGoogle Scholar
• 13. Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16(2), 152–160 (2015).
  Medline CASGoogle Scholar
• 14. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13(10), 983–992 (2012).
  Medline CASGoogle Scholar
• 15. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012).
  Medline CASGoogle Scholar
• 16. Hussain M, Fizazi K, Saad F et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 378(26), 2465–2474 (2018).
  Medline CASGoogle Scholar
• 17. Smith MR, Saad F, Chowdhury S et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378(15), 1408–1418 (2018).
  Medline CASGoogle Scholar
• 18. Kyriakopoulos CE, Chen YH, Carducci MA et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36(11), 1080–1087 (2018).
  Medline CASGoogle Scholar
• 19. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024), 1163–1177 (2016).
  Medline CASGoogle Scholar
• 20. Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377(4), 352–360 (2017). • Describes the results of the LATITUDE trial, which shows a benefit in addition of abiraterone acetate and prednisone to ADT for men with newly diagnosed mHSPC.
  Medline CASGoogle Scholar
• 21. James ND, De Bono JS, Spears MR et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377(4), 338–351 (2017).
  Medline CASGoogle Scholar
• 22. Fizazi K, Tran N, Fein L et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20(5), 686–700 (2019).
  Medline CASGoogle Scholar
• 23. Wallis CJD, Klaassen Z, Bhindi B et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur. Urol. 73(6), 834–844 (2018).
  Medline CASGoogle Scholar
• 24. Sydes MR, Spears MR, Mason MD et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 29(5), 1235–1248 (2018).
  Medline CASGoogle Scholar
• 25. Armstrong AJ, Szmulewitz RZ, Petrylak DP et al. ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37(32), 2974–2986 (2019). •• Describes the results of the interim analysis of the ARCHES trial indicating a benefit in treatment with ADT plus enzalutamide in mHSPC regardless of disease volume or prior docetaxel treatment.
  Medline CASGoogle Scholar
• 26. Chi KN, Agarwal N, Bjartell A et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381(1), 13–24 (2019). • Describes the results of the TITAN trial showing a benefit in using apalutamide already in mHSPC. It led to the inclusion of apalutamide in current treatment guidelines on mHSPC.
  Medline CASGoogle Scholar
• 27. Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121–131 (2019). • Describes the results of the ENZAMET trial which tested enzalutamide in mHSPC patients with an option for early docetaxel use.
  Medline CASGoogle Scholar
• 28. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787–790 (2009).
  Medline CASGoogle Scholar
• 29. Fizazi K, Scher HI, Miller K et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 15(10), 1147–1156 (2014).
  Medline CASGoogle Scholar
• 30. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371(5), 424–433 (2014).
  MedlineGoogle Scholar
• 31. Beer TM, Armstrong AJ, Rathkopf D et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the Phase 3 PREVAIL study. Eur. Urol. 71(2), 151–154 (2017).
  Medline CASGoogle Scholar
• 32. Loriot Y, Miller K, Sternberg CN et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 16(5), 509–521 (2015).
  Medline CASGoogle Scholar
• 33. De Bono JS, Chowdhury S, Feyerabend S et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >/=24 weeks in Europe. Eur. Urol. 74(1), 37–45 (2018).
  MedlineGoogle Scholar
• 34. Morris MJ, Heller G, Bryce AH et al. Alliance A031201: A phase IIItrial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 37(Suppl. 15), S5008 (2019). • Describes the results of the ALLIANCE trial, which tested the combined administration of abiraterone and prednisone with enzalutamide progressive metastasized castration resistant prostate cancer. The trial indicates no improvement in overall survival at an increased rate of toxicities on combination treatment with abiraterone and predinisone with enzalutamide.
  Google Scholar
• 35. Andrew J, Armstrong RZS, Petrylak Daniel et al. ARCHES: efficacy of androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer – outcomes from the overall population and subgroups by prior therapy. J. Clin. Oncol. 37(Suppl. 15), S5048 (2019).
  Google Scholar
• 36. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin. Pharmacokinet. 45(3), 235–252 (2006).
  Medline CASGoogle Scholar
• 37. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8(5), 391–401 (1998).
  Medline CASGoogle Scholar
• 38. Acharya M, Gonzalez M, Mannens G et al. A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica 43(4), 379–389 (2013).
  Medline CASGoogle Scholar
• 39. Agency EM. European Public Assessment Report (EPAR): Zytiga (abiraterone acetate). European Medicines Agency, London, UK (2016). www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf
  Google Scholar
• 40. Apalutamide for prostate cancer. Aust. Prescr. 42(1), 32–33 (2019).
  MedlineGoogle Scholar
• 41. Gibbons JA, De Vries M, Krauwinkel W et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin. Pharmacokinet. 54(10), 1057–1069 (2015).
  Medline CASGoogle Scholar
• 42. Antonarakis ES, Lu C, Luber B et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J. Clin. Oncol. 35(19), 2149–2156 (2017).
  Medline CASGoogle Scholar
• 43. Armstrong AJ, Halabi S, Luo J et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J. Clin. Oncol. 37(13), 1120–1129 (2019).
  Medline CASGoogle Scholar
• 44. Ma Y, Luk A, Young FP et al. Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies. Int. J. Mol. Sci. 17(8), 1264 (2016).
  Google Scholar